Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Patients taking Novo Nordisk’s anti-obesity jab sustained weight loss for up to four years and had a ...
Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable ...
FAT jabs could be the cancer hope of the future after early studies found they reduce the risk of tumours. The world’s top ...
The rapid rise of weight loss drugs Wegovy and Mounjaro is generating a host of new product lines as companies hope to land ...
A NEW weight loss drug could hijack the brain like a ‘Trojan horse’ to double weight loss. The drug could help the body to ...
In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...
Structure Therapeutics (NASDAQ: GPCR) might have something cooking that could one day unseat the likes of Novo Nordisk's (NYSE: NVO) Ozempic, a drug for type 2 diabetes, as well as its drug Wegovy, ...
Not only has the Danish economy benefited from the success of Ozempic and Wegovy, two more weight-management medications ...
La liste des vertus potentielles du Wegovy, le médicament anti-obésité de Novo Nordisk, continue de s’allonger. En mars dernier, la Food and Drug administration (FDA) a approuvé son usage ...
Les actions européennes progressent grâce aux valeurs technologiques à l'approche de la décision de la BCE 06/06 RE Novo Nordisk fait face à la concurrence en Chine pour l'ingrédient clé de ...